Trials / Completed
CompletedNCT01437852
StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
An Open-Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety and Efficacy of StrataGraft® Skin Tissue in Promoting the Healing of the Deep Partial-Thickness Component of Complex Skin Defects as an Alternative to Autografting
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Stratatech, a Mallinckrodt Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The proposed study is designed as a phase Ib open-label, dose-escalation, multicenter study evaluating the safety, tolerability, and efficacy of StrataGraft skin tissue in promoting the healing of the deep partial-thickness component of complex skin defects. The proposed study population will include patients with 3-49% Total Body Surface Area (TBSA) complex skin defects including a deep partial-thickness component resulting from thermal injury. The study has been designed to focus on the evaluation of safety and tolerability of prolonged exposure to increasing amounts of a single application of StrataGraft skin tissue, while also assessing the potential for StrataGraft tissue to promote healing of the deep partial-thickness component of these complex skin defects as an alternative to donor site harvesting and autografting. Targeted enrollment for this study is up to 30 patients with complex skin defects due to thermal burns which require surgical excision and autografting. Subjects will be sequentially enrolled in two cohorts of increasing treatment area receiving StrataGraft skin tissue that has been stored refrigerated prior to clinical use. A third cohort will receive StrataGraft skin tissue which has been stored cryopreserved and thawed in the operating room just prior to grafting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | StrataGraft Skin Tissue |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2014-01-01
- Completion
- 2014-10-01
- First posted
- 2011-09-21
- Last updated
- 2019-10-16
- Results posted
- 2018-12-13
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01437852. Inclusion in this directory is not an endorsement.